<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="letter"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.0 20120330//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-journalpublishing1.dtd?><?SourceDTD.Version 1.0?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">BJPsych Bull</journal-id><journal-id journal-id-type="iso-abbrev">BJPsych Bull</journal-id><journal-id journal-id-type="publisher-id">BJB</journal-id><journal-title-group><journal-title>BJPsych Bulletin</journal-title></journal-title-group><issn pub-type="ppub">2056-4694</issn><issn pub-type="epub">2056-4708</issn><publisher><publisher-name>Cambridge University Press</publisher-name><publisher-loc>Cambridge, UK</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">6048734</article-id><article-id pub-id-type="doi">10.1192/bjb.2018.32</article-id><article-id pub-id-type="pii">S2056469418000323</article-id><article-id pub-id-type="publisher-id">00032</article-id><article-categories><subj-group subj-group-type="heading"><subject>Correspondence</subject></subj-group></article-categories><title-group><article-title>Ideology over evidence?</article-title><alt-title alt-title-type="left-running">Correspondence</alt-title><alt-title alt-title-type="right-running">Correspondence</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Jauhar</surname><given-names>Sameer</given-names></name><role>Senior Research Fellow</role><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><name><surname>Young</surname><given-names>Allan H.</given-names></name><role>Director</role><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff id="aff1"><addr-line>Centre for Affective Disorders</addr-line>, <institution>Institute of Psychiatry</institution>, <addr-line>Psychology and Neuroscience</addr-line>, <institution>King's College</institution>, <addr-line>London</addr-line></aff><aff id="aff2"><addr-line>Research Fellow</addr-line>, <addr-line>Centre for Affective Disorders</addr-line>, <institution>Institute of Psychiatry</institution>, <addr-line>Psychology and Neuroscience</addr-line>, <institution>King's College;</institution> email: <email>sameer.jauhar@kcl.ac.uk</email></aff><pub-date pub-type="ppub"><month>6</month><year>2018</year></pub-date><volume>42</volume><issue>3</issue><fpage>130</fpage><lpage>131</lpage><permissions><copyright-statement>&#x000a9; The Authors 2018</copyright-statement><copyright-year>2018</copyright-year><copyright-holder>The Authors</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p><!--CREATIVE COMMONS-->This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xlink:title="pdf" xlink:href="S2056469418000323a.pdf"/><counts><ref-count count="8"/><page-count count="2"/></counts></article-meta></front><body><p>In her narrative, Dr Moncrieff makes assertions about depressive illness, antidepressants, and psychotropic medications.<xref rid="ref1" ref-type="bibr"><sup>1</sup></xref> Her main points are that these medications are not clinically effective when using rating scales, and that the models proposed for antidepressant action are erroneous. We would suggest that the narrative reflects ideology, as opposed to evidence, and should be interpreted accordingly.</p><p>First, a 1969 narrative supplementary review is given as an example of the lack of efficacy of tricyclic and older antidepressants. A more recent (and comprehensive) review found significant benefits for monoamine oxidase inhibitors over placebo, which were surpassed by tricyclics.<xref rid="ref2" ref-type="bibr"><sup>2</sup></xref> The argument is then made that changes on the Hamilton Rating Scale for Depression (HRSD) are minimal, in comparison with placebo, and that differences are clinically insignificant when the Clinical Global Impression (CGI) scale is used, citing among other reviews the Kirsch meta-analysis (where the effect size was 0.31<xref rid="ref3" ref-type="bibr"><sup>3</sup></xref>). A similar effect size was seen in a recent analysis of over 500 studies, which reported odds ratios of between 1.37 and 2.13 for response compared with placebo.<xref rid="ref4" ref-type="bibr"><sup>4</sup></xref></p><p>In focusing the argument on change in total HRSD score, Dr Moncrieff appears unaware that the scale was never intended to measure change. A more robust way of analysing it was recently demonstrated, using the rating of subjective mood (item 1 on the HRSD), which would be akin to the CGI. This avoided the influence of antidepressant side-effects on the scale, and found clear benefits for paroxetine and citalopram over placebo.<xref rid="ref5" ref-type="bibr"><sup>5</sup></xref></p><p>A study cited to indicate severity of depression did not predict outcome, evaluated the short-term efficacy of antidepressants and was not intended to test the hypothesis of severity, with the authors reporting significant benefits of fluoxetine over placebo in adults (improvement of approximately 35%).<xref rid="ref6" ref-type="bibr"><sup>6</sup></xref> The 1964 Medical Research Council trial (which showed the efficacy of electroconvulsive therapy) is given as evidence of lack of effect of severity on response; however, the statement that antidepressants did not outperform placebo is not surprising, given that the dose of imipramine was 50&#x000a0;mg and that of phenelzine 15&#x000a0;mg. A more recent and influential publicly funded study (cited over 3000 times in Google Scholar) showed the effectiveness of imipramine (at a therapeutic dose of around 185&#x000a0;mg) in people with severe depression, in comparison with psychological therapies (cognitive&#x02013;behavioural therapy and interpersonal therapy). These therapies showed little benefit over placebo in this group.<xref rid="ref7" ref-type="bibr"><sup>7</sup></xref></p><p>The rest of the narrative dwells on &#x02018;disease-centred&#x02019; models of psychiatric illness, as an alternative to the current &#x02018;targeting a brain abnormality&#x02019; approach. We are unaware of modern psychiatry relying on the neurotransmitter models she discusses; the field has moved on significantly, and most neuroscientists would point to more nuanced models involving effects on neural networks and plasticity.<xref rid="ref8" ref-type="bibr"><sup>8</sup></xref> The predominant references cited here are Dr Moncrieff's own hypotheses.</p><p>In summary, we would suggest that Dr Moncrieff's narrative is selective at best, and on cursory examination there is little effort to appraise the literature in a scientifically objective manner. One cannot help but assume that this opinion piece represents ideology over evidence, and therefore any interpretation should be cautious.</p><p>Declaration of Interests</p><p>Professor Young has the following disclosures: Employed by King&#x02019;s College London; Honorary Consultant SLaM (NHS UK); paid lectures and advisory boards for the following companies with drugs used in affective and related disorders: Astrazenaca, Eli Lilly, Lundbeck, Sunovion, Servier, Livanova, Janssen; No share holdings in pharmaceutical companies; lead Investigator for Embolden Study (AZ), BCI Neuroplasticity study and Aripiprazole Mania Study; Investigator initiated studies from AZ, Eli Lilly, Lundbeck, Wyeth, Janssen. Grant funding (past and present): NIMH (USA); CIHR (Canada); NARSAD (USA); Stanley Medical Research Institute (USA); MRC (UK); Wellcome Trust (UK); Royal College of Physicians (Edin); BMA (UK); UBC-VGH Foundation (Canada); WEDC (Canada); CCS Depression Research Fund (Canada); MSFHR (Canada); NIHR (UK). Janssen (UK)</p></body><back><ref-list id="reflist1"><ref id="ref1"><label>1</label><mixed-citation publication-type="journal"><name><surname>Moncrieff</surname><given-names>J.</given-names></name>
<article-title>Antidepressants are not antidepressants &#x02013; an alternative approach to drug action and implications for the use of antidepressants</article-title>. <source>BJPsych Bull</source>
<year>2018</year>; <volume>42</volume>(<issue>1</issue>): <fpage>42</fpage>&#x02013;4.<pub-id pub-id-type="pmid">29388527</pub-id></mixed-citation></ref><ref id="ref2"><label>2</label><mixed-citation publication-type="journal"><name><surname>Thase</surname><given-names>ME</given-names></name>, <name><surname>Trivedi</surname><given-names>MH</given-names></name>, <name><surname>Rush</surname><given-names>AJ.</given-names></name>
<article-title>MAOIs in the contemporary treatment of depression</article-title>. <source>Neuropsychopharmacology</source>
<year>1995</year>; <volume>12</volume>(<issue>3</issue>): <fpage>185</fpage>&#x02013;<lpage>219</lpage>.<pub-id pub-id-type="pmid">7612154</pub-id></mixed-citation></ref><ref id="ref3"><label>3</label><mixed-citation publication-type="journal"><name><surname>Kirsch</surname><given-names>I</given-names></name>, <name><surname>Deacon</surname><given-names>BJ</given-names></name>, <name><surname>Huedo-Medina</surname><given-names>TB</given-names></name>, <name><surname>Scoboria</surname><given-names>A</given-names></name>, <name><surname>Moore</surname><given-names>TJ</given-names></name>, <name><surname>Johnson</surname><given-names>BT.</given-names></name>
<article-title>Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration</article-title>. <source>PLoS Med</source>
<year>2008</year>; <volume>5</volume>(<issue>2</issue>): <elocation-id>e45</elocation-id>.<pub-id pub-id-type="pmid">18303940</pub-id></mixed-citation></ref><ref id="ref4"><label>4</label><mixed-citation publication-type="journal"><name><surname>Cipriani</surname><given-names>A</given-names></name>, <name><surname>Furukawa</surname><given-names>TA</given-names></name>, <name><surname>Salanti</surname><given-names>G</given-names></name>, <name><surname>Chaimani</surname><given-names>A</given-names></name>, <name><surname>Atkinson</surname><given-names>LZ</given-names></name>, <name><surname>Ogawa</surname><given-names>Y</given-names></name>, <etal/>
<article-title>Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis</article-title>. <source>Lancet</source>
<year>2018</year>; <volume>391</volume>(<issue>10128</issue>): <fpage>1357</fpage>&#x02013;66.<pub-id pub-id-type="pmid">29477251</pub-id></mixed-citation></ref><ref id="ref5"><label>5</label><mixed-citation publication-type="journal"><name><surname>Hieronymus</surname><given-names>F</given-names></name>, <name><surname>Lisinski</surname><given-names>A</given-names></name>, <name><surname>Nilsson</surname><given-names>S</given-names></name>, <name><surname>Eriksson</surname><given-names>E.</given-names></name>
<article-title>Efficacy of selective serotonin reuptake inhibitors in the absence of side effects: a mega-analysis of citalopram and paroxetine in adult depression</article-title>. <source>Mol Psychiatry</source>
<year>2017</year>; doi: <pub-id pub-id-type="doi">10.1038/mp.2017.147</pub-id>.</mixed-citation></ref><ref id="ref6"><label>6</label><mixed-citation publication-type="journal"><name><surname>Gibbons</surname><given-names>RD</given-names></name>, <name><surname>Hur</surname><given-names>K</given-names></name>, <name><surname>Brown</surname><given-names>CH</given-names></name>, <name><surname>Davis</surname><given-names>JM</given-names></name>, <name><surname>Mann</surname><given-names>JJ.</given-names></name>
<article-title>Benefits from antidepressants: synthesis of 6-week patient-level outcomes from double-blind placebo-controlled randomized trials of fluoxetine and venlafaxine</article-title>. <source>Arch Gen Psychiatry</source>
<year>2012</year>; <volume>69</volume>(<issue>6</issue>): <fpage>572</fpage>&#x02013;9.<pub-id pub-id-type="pmid">22393205</pub-id></mixed-citation></ref><ref id="ref7"><label>7</label><mixed-citation publication-type="journal"><name><surname>Elkin</surname><given-names>I</given-names></name>, <name><surname>Shea</surname><given-names>MT</given-names></name>, <name><surname>Watkins</surname><given-names>JT</given-names></name>, <name><surname>Imber</surname><given-names>SD</given-names></name>, <name><surname>Sotsky</surname><given-names>SM</given-names></name>, <name><surname>Collins</surname><given-names>JF</given-names></name>, <etal/>
<article-title>National Institute of Mental Health Treatment of Depression Collaborative Research Program: general effectiveness of treatments</article-title>. <source>Arch Gen Psychiatry</source>
<year>1989</year>; <volume>46</volume>(<issue>11</issue>): <fpage>971</fpage>&#x02013;82.<pub-id pub-id-type="pmid">2684085</pub-id></mixed-citation></ref><ref id="ref8"><label>8</label><mixed-citation publication-type="journal"><name><surname>Morrison</surname><given-names>PD</given-names></name>, <name><surname>Murray</surname><given-names>RM.</given-names></name>
<article-title>The antipsychotic landscape: dopamine and beyond</article-title>. <source>Ther Adv Psychopharmacol</source>
<year>2018</year>; <volume>8</volume>(<issue>4</issue>): <fpage>127</fpage>&#x02013;35.<pub-id pub-id-type="pmid">29607005</pub-id></mixed-citation></ref></ref-list></back></article>